MYC and cancer: Treatment with estradiol, epoch and catenin, EZH2 combines to form a complex on MYC promoter that activates transcription independently of histone methyltransferase activity in TNBC.17,22,25,26 These findings suggest that EZH2 plays important roles in the transcription regulation in cancer cells and could be a promising therapeutic target for cancer therapy, including TNBC.